Gabapentin (Epilepsy) updated on 04-22-2025

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6060
R15752		 Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 Facial cleft 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 7.05 [0.28;176.78] C 0/31   1/647 1 31
ref
Total 1 studies 7.05 [0.28;176.78] 1 31
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Morrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 1 7.05[0.28; 176.78]1310%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Gabapentin) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 7.05[0.28; 176.78]131 -NAMorrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 1 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 7.05[0.28; 176.78]131 -NAMorrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 7.05[0.28; 176.78]131 -NAMorrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 1 All studiesAll studies 7.05[0.28; 176.78]131 -NAMorrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 10.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 7.05[0.28; 176.78]131 -NAMorrow (Gabapentin) (Controls exposed to Lamotrigine, sick), 2006 10.510.01.0